Rutgers University Study of the Genetics of Blood Cancers

The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Blood Cancers Blood Cancer Hematologic Cancer Hematologic Diseases Hematologic Malignancies Hematologic Neoplasm Hematologic Neoplasms Hematologic Tumors Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Plasma Cell

Age range

18 year–110 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Rutgers University

Piscataway, New Jersey, 08854, United States

Location contact

Tara Matise, PhD

CONTACT

[email protected]

848-445-3125

Tara Matise, PhD

PRINCIPAL_INVESTIGATOR

About this study

This is an online research study to learn more about how genes affect your risk of blood cancers. No office visit is required and in return, participants may receive information about their genetic ancestry for free. This study will increase our understanding of the genetic basis of blood cancers, which is a crucial step in drug development to improve current treatment options. We seek a diverse population because diversity among participants maximizes the usefulness of the data. Participants will use our online study portal to answer questions about their health and provide their DNA via a saliva sample using a pre-paid mailer. Participation takes approximately 20 minutes. Participants will be invited to share data from their electronic health records, but this is not required for study participation. We keep participants engaged with short monthly newsletters.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age 18 years or older
currently living in the United States
have access to the internet and a computer, laptop, tablet or smartphone
willing to provide written informed consent for participation
willing to provide DNA via a saliva sample using a collection kit mailed to your home
willing to complete a survey with questions about health related to the study of blood cancer.

Exclusion criteria

Not able to meet or fulfill any of the inclusion criteria

Treatment and study plan

Primary outcomes

Genetic risk variants associated with blood cancer

Time frame: 2 years

Genetic factors will be measured through whole exome sequencing and genome-wide genotyping array, and then correlated with blood cancer subtype.

Study contacts

Contact information is provided by the study sponsor or research team.

Tara Matise, PhD

CONTACT

[email protected]

848-445-3125

Sponsors and collaborators

Lead sponsor

Rutgers, The State University of New Jersey

Other

Registry information

Official study title

The Rutgers University Study of the Genetics of Blood Cancers

Important dates

Study start: 2026
Primary completion: 2029
Study completion: 2029
First posted: Jul 20, 2026
Registry last updated: Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting